Navigation Links
Bayer Introduces Fitness Program for Children and Young Adults with Hemophilia A

WAYNE, N.J., Oct. 26 /PRNewswire/ -- Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives.  "Living Fit! A Joint Effort" is a unique strength training, fitness and wellness program created to increase awareness of the importance of exercise and nutrition among this population and their caregivers.

Fitness and healthy eating are especially important because strong muscles and a lower body weight may help maintain joint health, an important consideration for people with hemophilia A.  According to the Centers for Disease Control and Prevention, the rates of overweight and obesity among children and adolescents with hemophilia are similar to those among the general population, which are currently at epidemic proportions(1).

Living Fit! is designed to help protect and maintain joints before they become damaged from repeated bleeds.  The program offers videos, information and resources, available at, designed to promote a healthy lifestyle and engagement in appropriate types of exercise.  It focuses on four pillars of health: general wellness, nutrition, cardiovascular exercises and strengthening exercises.  

Living Fit! was inspired by Corey Pierce, a 24-year-old with hemophilia A and a former participant in the Bayer Hemophilia Leadership Development Program.

"I am thrilled to be able to introduce Living Fit! to help people like me maintain a healthy body – and healthy joints – as we continue to grow and develop into adulthood," Pierce said.  "It is my hope that the program can be a valuable, relevant resource for future generations of young people living with hemophilia."

A Living Fit! symposium is being held at November's annual meeting of the National Hemophilia Foundation to further encourage members of the hemophilia community to embrace fitness.  The symposium will feature the Season 5 at-home winner from NBC's "The Biggest Loser®," Bernie Salazar, and nutrition expert Rebecca Scritchfield, RD, who will be there to help motivate attendees.

Living Fit! also offers FactorTrack™, the first free, personal and interactive mobile application that helps make it easier to track and record factor infusions.  Living Fit! also includes downloadable fitness guidelines, designed by a team of physical therapists who work with people with hemophilia A.  FactorTrack and the guidelines are available at  In addition, a Living Fit! Patient Kit, including educational materials and a DVD with demonstrations of the program's components, are available through Bayer Hemophilia Account Executives.

For more information about Living Fit!, please visit

About Hemophilia A

Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs.  Approximately one in 5,000 males born in the United States has hemophilia.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  As a specialty pharmaceutical company, Bayer HealthCare Pharmaceuticals provides products for Diagnostic Imaging, General Medicine, Hematology, Neurology, Oncology and Women's Healthcare.  The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

BAYER and the Bayer Cross are registered trademarks of Bayer.  Living Fit! A Joint Effort and FactorTrack are trademarks of Bayer.

(1) -- accessed 10-04-2010

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... NC (PRWEB) , ... November 27, 2015 , ... A ... effective ways to treat it. Surviving Mesothelioma has just posted the findings on ... at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ProSidebar: ... in Final Cut Pro X. With ProSidebar: Fasion, video editors can easily add ... ProSidebar as a minimalist title opener. Utilize presets featuring self-animating drop zones, lines, ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, ... posters. This is one of Joplin's most famous and beautiful concert posters. The concert ... Michigan in Ann Arbor. The According to Hawley, "It is hard to believe that ...
Breaking Medicine News(10 mins):